BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2012;27:1329-1335. [PMID: 22606978 DOI: 10.1111/j.1440-1746.2012.07186.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, Vilstrup H, Jalan R. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol. 2020;73:1526-1547. [PMID: 33097308 DOI: 10.1016/j.jhep.2020.07.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 21.0] [Reference Citation Analysis]
2 Rathi S, Fagan A, Wade JB, Chopra M, White MB, Ganapathy D, Acharya C, Dhiman RK, Bajaj JS. Patient Acceptance of Lactulose Varies Between Indian and American Cohorts: Implications for Comparing and Designing Global Hepatic Encephalopathy Trials. J Clin Exp Hepatol 2018;8:109-15. [PMID: 29892171 DOI: 10.1016/j.jceh.2017.11.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
3 Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017;5:138-147. [PMID: 28533911 DOI: 10.1093/gastro/gox013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
4 Kockerling D, Nathwani R, Forlano R, Manousou P, Mullish BH, Dhar A. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019;25:888-908. [PMID: 30833797 DOI: 10.3748/wjg.v25.i8.888] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
5 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Reference Citation Analysis]
6 Ghobadi Pour M, Mirazi N, Alaei H, Moradkhani S, Rajaei Z, Monsef Esfahani A. Effects of lactulose and silymarin on liver enzymes in cirrhotic rats. Can J Physiol Pharmacol 2017;95:522-9. [PMID: 28281782 DOI: 10.1139/cjpp-2016-0454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gluud LL, Vilstrup H, Morgan MY. Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis. Hepatology 2016;64:908-22. [PMID: 27081787 DOI: 10.1002/hep.28598] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 8.4] [Reference Citation Analysis]
8 Peck-Radosavljevic M, Angeli P, Cordoba J, Farges O, Valla D. Managing complications in cirrhotic patients. United European Gastroenterol J 2015;3:80-94. [PMID: 25653862 DOI: 10.1177/2050640614560452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
9 Riggio O, Amodio P, Farcomeni A, Merli M, Nardelli S, Pasquale C, Pentassuglio I, Gioia S, Onori E, Piazza N. A Model for Predicting Development of Overt Hepatic Encephalopathy in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2015;13:1346-1352. [PMID: 25572976 DOI: 10.1016/j.cgh.2014.12.025] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
10 Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;CD003044. [PMID: 27153247 DOI: 10.1002/14651858.cd003044.pub4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
11 Hadjihambi A, Arias N, Sheikh M, Jalan R. Hepatic encephalopathy a critical current review. Hepatol Int. 2018;12:135-147. [PMID: 28770516 DOI: 10.1007/s12072-017-9812-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 14.5] [Reference Citation Analysis]
12 Vong LB, Ibayashi Y, Lee Y, Ngo D, Nishikawa Y, Nagasaki Y. Poly(ornithine)-based self-assembling drug for recovery of hyperammonemia and damage in acute liver injury. Journal of Controlled Release 2019;310:74-81. [DOI: 10.1016/j.jconrel.2019.08.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
13 Moratalla A, Ampuero J, Bellot P, Gallego-Durán R, Zapater P, Roger M, Figueruela B, Martínez-Moreno B, González-Navajas JM, Such J, Romero-Gómez M, Francés R. Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. Liver Int 2017;37:212-23. [PMID: 27388776 DOI: 10.1111/liv.13200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
14 Hsu MC, Weber CN, Stavropoulos SW, Clark TW, Trerotola SO, Shlansky-Goldberg RD, Soulen MC, Nadolski GJ. Passive expansion of sub-maximally dilated transjugular intrahepatic portosystemic shunts and assessment of clinical outcomes. World J Hepatol 2017;9:603-12. [PMID: 28515846 DOI: 10.4254/wjh.v9.i12.603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
15 Kimer N, Krag A, Bendtsen F, Møller S, Gluud LL; Cochrane Hepato-Biliary Group. Rifaximin for people with hepatic encephalopathy. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd011585] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
16 Ventura-Cots M, Concepción M, Arranz JA, Simón-Talero M, Torrens M, Blanco-Grau A, Fuentes I, Suñé P, Alvarado-Tapias E, Gely C, Roman E, Mínguez B, Soriano G, Genescà J, Córdoba J. Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients. Therap Adv Gastroenterol 2016;9:823-35. [PMID: 27803737 DOI: 10.1177/1756283X16658252] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
17 Mancini A, Campagna F, Amodio P, Tuohy KM. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. Food Funct. 2018;9:1373-1388. [PMID: 29485654 DOI: 10.1039/c7fo01528c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
18 Teperman LW. Impact of pretransplant hepatic encephalopathy on liver posttransplantation outcomes. Int J Hepatol 2013;2013:952828. [PMID: 24324895 DOI: 10.1155/2013/952828] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
19 Henkel S, Vetterly C, Squires R, McKiernan P, Squires J. Pharmacological management of portal hypertension and its complications in children: lessons from adults and opportunities for the future. Expert Opin Pharmacother 2021;22:291-304. [PMID: 33074032 DOI: 10.1080/14656566.2020.1825685] [Reference Citation Analysis]
20 Pranami D, Sharma R, Pathak H. Lactulose: a prebiotic, laxative and detoxifying agent. Drugs Ther Perspect 2017;33:228-33. [DOI: 10.1007/s40267-017-0384-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
21 Li X, Gan D, Li Y, Zhang P, Li Z, Du H, Zhang L, Cheng Y, Zhang Y, Liang Y, Ye Y. JianPi HuaZhuo XingNao formula (Chinese herbal medicine) for the treatment of minimal hepatic encephalopathy: a protocol for a randomized, placebo-controlled pilot trial. Medicine (Baltimore) 2018;97:e0526. [PMID: 29703024 DOI: 10.1097/MD.0000000000010526] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Rahimi RS, Rockey DC. End-stage liver disease complications. Curr Opin Gastroenterol. 2013;29:257-263. [PMID: 23429468 DOI: 10.1097/mog.0b013e32835f43b0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
23 Bajaj JS, Thacker LR, Heuman DM, Fuchs M, Sterling RK, Sanyal AJ, Puri P, Siddiqui MS, Stravitz RT, Bouneva I, Luketic V, Noble N, White MB, Monteith P, Unser A, Wade JB. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology. 2013;58:1122-1132. [PMID: 23389962 DOI: 10.1002/hep.26309] [Cited by in Crossref: 111] [Cited by in F6Publishing: 91] [Article Influence: 13.9] [Reference Citation Analysis]
24 Suraweera D, Sundaram V, Saab S. Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut Liver. 2016;10:509-519. [PMID: 27377741 DOI: 10.5009/gnl15419] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
25 Victor DW 3rd, Quigley EM. Hepatic encephalopathy involves interactions among the microbiota, gut, brain. Clin Gastroenterol Hepatol. 2014;12:1009-1011. [PMID: 24462627 DOI: 10.1016/j.cgh.2014.01.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
26 Moran S, López-Sánchez M, Milke-García MDP, Rodríguez-Leal G. Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis. World J Gastroenterol 2021;27:3050-63. [PMID: 34168407 DOI: 10.3748/wjg.v27.i22.3050] [Reference Citation Analysis]
27 Matoori S, Leroux JC. Recent advances in the treatment of hyperammonemia. Adv Drug Deliv Rev 2015;90:55-68. [PMID: 25895618 DOI: 10.1016/j.addr.2015.04.009] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 9.7] [Reference Citation Analysis]
28 Rathi S, Chopra M, Chouduri G, Sharma P, Madan K, Chhabra M, Rai RR, Govil A, Konar A, Goenka M, Agarwal M, Mukherjee J, Thorat V, Salunkhe S, Abraham P, Nagral A, Jhaveri A, Bhat N, Varghese J, R S A, Ravishankar, Reddy DC, Dhiman RK. Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Cross-Sectional, Clinicoepidemiological, Multicenter, Nationwide Study in India: The PREDICT Study. J Clin Exp Hepatol 2019;9:476-83. [PMID: 31516264 DOI: 10.1016/j.jceh.2018.09.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Waghray A, Waghray N, Mullen K. Management of covert hepatic encephalopathy. J Clin Exp Hepatol 2015;5:S75-81. [PMID: 26041963 DOI: 10.1016/j.jceh.2014.02.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
30 Liu A, Perumpail RB, Kumari R, Younossi ZM, Wong RJ, Ahmed A. Advances in cirrhosis: Optimizing the management of hepatic encephalopathy. World J Hepatol 2015;7:2871-9. [PMID: 26692331 DOI: 10.4254/wjh.v7.i29.2871] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
31 Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;4:CD003044. [PMID: 27089005 DOI: 10.1002/14651858.cd003044.pub3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 6.4] [Reference Citation Analysis]
32 Torres-vega MA, Vargas-jerónimo RY, Montiel-martínez AG, Muñoz-fuentes RM, Zamorano-carrillo A, Pastor AR, Palomares LA. Delivery of glutamine synthetase gene by baculovirus vectors: a proof of concept for the treatment of acute hyperammonemia. Gene Ther 2015;22:58-64. [DOI: 10.1038/gt.2014.89] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
33 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. [PMID: 34228859 DOI: 10.1111/hepr.13678] [Reference Citation Analysis]
34 Sharma P, Sharma BC. Disaccharides in the treatment of hepatic encephalopathy. Metab Brain Dis 2013;28:313-20. [PMID: 23456517 DOI: 10.1007/s11011-013-9392-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
35 De Rui M, Montagnese S, Amodio P. Recent developments in the diagnosis and treatment of covert/minimal hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2016;10:443-50. [PMID: 26758861 DOI: 10.1586/17474124.2016.1141675] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
36 Ridola L, Cardinale V, Riggio O. The burden of minimal hepatic encephalopathy: From diagnosis to therapeutic strategies. Ann Gastroenterol. 2018;31:151-164. [PMID: 29507462 DOI: 10.20524/aog.2018.0232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
37 Sandrasegaran K, Cui E, Elkady R, Gasparis P, Borthakur G, Tann M, Liangpunsakul S. Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis? Eur Radiol 2018;28:4215-24. [DOI: 10.1007/s00330-018-5366-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
38 Liu A, Yoo ER, Siddique O, Perumpail RB, Cholankeril G, Ahmed A. Hepatic encephalopathy: what the multidisciplinary team can do. J Multidiscip Healthc. 2017;10:113-119. [PMID: 28392702 DOI: 10.2147/jmdh.s118963] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
39 Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715-735. [PMID: 25042402 DOI: 10.1002/hep.27210] [Cited by in Crossref: 879] [Cited by in F6Publishing: 634] [Article Influence: 125.6] [Reference Citation Analysis]
40 Rahimi RS, Rockey DC. Hepatic encephalopathy: how to test and treat. Current Opinion in Gastroenterology 2014;30:265-71. [DOI: 10.1097/mog.0000000000000066] [Cited by in Crossref: 10] [Article Influence: 1.4] [Reference Citation Analysis]
41 American Association for the Study of Liver Diseases. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61:642-659. [PMID: 25015420 DOI: 10.1016/j.jhep.2014.05.042] [Cited by in Crossref: 212] [Cited by in F6Publishing: 151] [Article Influence: 30.3] [Reference Citation Analysis]
42 Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2:CD008716. [PMID: 28230908 DOI: 10.1002/14651858.cd008716.pub3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
43 Alvares-da-Silva MR, de Araujo A, Vicenzi JR, da Silva GV, Oliveira FB, Schacher F, Oliboni L, Magnus A, Kruel LP, Prieb R. Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:956-963. [PMID: 24033861 DOI: 10.1111/hepr.12235] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
44 Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol. 2019;31:434-450. [PMID: 30444745 DOI: 10.1097/meg.0000000000001311] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
45 Waghray N, Waghray A, Mullen K. Treatment options for covert hepatic encephalopathy. Curr Treat Options Gastroenterol. 2014;12:229-241. [PMID: 24623592 DOI: 10.1007/s11938-014-0014-y] [Reference Citation Analysis]
46 Nakanishi H, Kurosaki M, Nakanishi K, Tsuchiya K, Noda T, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Itakura J, Anami K, Asahina Y, Enomoto N, Higuchi T, Izumi N. Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: Evaluation by near-infrared spectroscopy. Hepatol Res 2014;44:319-26. [PMID: 23607661 DOI: 10.1111/hepr.12127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
47 Ridola L, Nardelli S, Gioia S, Riggio O. How to design a multicenter clinical trial in Hepatic Encephalopathy. JCEH 2018 in press. . [PMID: 30765947 DOI: 10.1016/j.jceh.2018.02.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
48 Yanny B, Winters A, Boutros S, Saab S. Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach. Clin Liver Dis 2019;23:607-23. [PMID: 31563214 DOI: 10.1016/j.cld.2019.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
49 Nardelli S, Allampati S, Riggio O, Mullen KD, Prakash R, Gioia S, Unser A, White MB, Fagan AC, Wade JB, Farcomeni A, Gavis EA, Bajaj JS. Hepatic Encephalopathy Is Associated with Persistent Learning Impairments Despite Adequate Medical Treatment: A Multicenter, International Study. Dig Dis Sci 2017;62:794-800. [PMID: 28039670 DOI: 10.1007/s10620-016-4425-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
50 Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol 2014; 12: 1003-8. e1. [PMID: 24246768 DOI: 10.1016/j.cgh.2013.11.006] [Cited by in Crossref: 96] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
51 Butterworth RF. Hepatic Encephalopathy. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 615-29. [DOI: 10.1002/9781119436812.ch48] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
52 Lee EW, Lee AE, Saab S, Kee ST. Retrograde Transvenous Obliteration (RTO): A New Treatment Option for Hepatic Encephalopathy. Dig Dis Sci 2020;65:2483-91. [DOI: 10.1007/s10620-020-06050-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
53 Poh Z, Chang PE. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol. 2012;2012:480309. [PMID: 23133760 DOI: 10.1155/2012/480309] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
54 Jia JD. Lactulose in the treatment of hepatic encephalopathy: new evidence for an old modality. J Gastroenterol Hepatol 2012;27:1262-3. [PMID: 22823914 DOI: 10.1111/j.1440-1746.2012.07177.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
55 Ding JH, Jin Z, Yang XX, Lou J, Shan WX, Hu YX, Du Q, Liao QS, Xie R, Xu JY. Role of gut microbiota via the gut-liver-brain axis in digestive diseases. World J Gastroenterol 2020;26:6141-62. [PMID: 33177790 DOI: 10.3748/wjg.v26.i40.6141] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
56 Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, Vilstrup H. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis. 2013;28:221-225. [PMID: 23275147 DOI: 10.1007/s11011-012-9372-0] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 6.8] [Reference Citation Analysis]
57 Kimer N, Krag A, Møller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014;40:123-32. [DOI: 10.1111/apt.12803] [Cited by in Crossref: 109] [Cited by in F6Publishing: 70] [Article Influence: 15.6] [Reference Citation Analysis]